CUBT (Curative Biotechnology) Current Deferred Revenue: $0.00 Mil (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Curative Biotechnology Current Deferred Revenue?

Curative Biotechnology CUBT Current Deferred Revenue is $0.00 Mil as of Mar. 2023.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Curative Biotechnology's current deferred revenue for the quarter that ended in Mar. 2023 was $0.00 Mil.

Curative Biotechnology Current Deferred Revenue Related Terms

Curative Biotechnology Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Curative Biotechnology's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Curative Biotechnology Current Deferred Revenue Chart

Curative Biotechnology Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Current Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Curative Biotechnology Quarterly Data
Dec16 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
What does a Current Deferred Revenue of $0.00 Mil mean?
Curative Biotechnology (CUBT) has a Current Deferred Revenue of $0.00 Mil as of Mar. 2023. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Curative Biotechnology and its competitors.
Is Curative Biotechnology's Current Deferred Revenue too high?
Curative Biotechnology's current Current Deferred Revenue is $0.00 Mil.
How does Curative Biotechnology's Current Deferred Revenue compare to ORGS and SNSE?
Curative Biotechnology's Current Deferred Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Curative Biotechnology and its competitors. Curative Biotechnology's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Curative Biotechnology stock overvalued right now?
Curative Biotechnology (CUBT) has a current Current Deferred Revenue of $0.00 Mil. The current Current Deferred Revenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Curative Biotechnology (CUBT), the current Current Deferred Revenue is $0.00 Mil as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Curative Biotechnology Business Description

Address 3801 PGA Boulevard, Suite 600, Palm Beach Gardens, FL, USA, 33410
Curative Biotechnology Inc is a development-stage biomedical company focusing on novel treatments for rare diseases. The Company is identifying, acquiring, and developing disease-modifying therapeutic drug candidates with a concentration on rare disease indications. Curative Biotech currently has ongoing programs in three different therapeutic areas: degenerative eye disease, infectious disease, and neuro-oncology. The Company is now concentrating its energy and resources on its degenerative eye disease platform.